Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II

被引：10
|
作者：
Duhoux, Francois P.
Jager, Agnes
Dirix, Luc Yves
Huizing, Manon Thirza
Jerusalem, Guy Heinrich Maria
Vuylsteke, Peter
De Cuypere, Eveline
Breiner, Doris
Mueller, Christian
Brignone, Chrystelle
Triebel, Frederic
机构：
[1] Clin Univ Saint Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium
[2] Catholic Univ Louvain, Inst Rech Experimentale & Clin Pole MIRO, Brussels, Belgium
[3] Erasmus MC Canc Inst, Rotterdam, Netherlands
[4] GZA St Augustinus, Oncol Cent GZA, TCRU, Antwerp, Belgium
[5] Univ Antwerp Hosp, Edegem, Belgium
[6] Univ Liege, Liege, Belgium
[7] CHU Sart Tilman Liege, Liege, Belgium
[8] Catholic Univ Louvain, CHU UCL Namur, Namur, Belgium
[9] Gen Hosp AZ Sint Jan Brugge Oostende, Brugge, Belgium
[10] Immutep, Clin Dev, Berlin, Germany
[11] Immutep, Res & Dev, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1050
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Rebecca Dent
    Mafalda Oliveira
    Steven J. Isakoff
    Seock-Ah Im
    Marc Espié
    Sibel Blau
    Antoinette R. Tan
    Cristina Saura
    Matthew J. Wongchenko
    Na Xu
    Denise Bradley
    Sarah-Jayne Reilly
    Aruna Mani
    Sung-Bae Kim
    Breast Cancer Research and Treatment, 2021, 189 : 377 - 386
  • [32] Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
    Krebs, M. G.
    Tarruella, M. Majem
    Forster, M.
    Peguero, J. A.
    Clay, T.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    de Speville, B. Doger
    Bajaj, P.
    Mueller, C.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S33 - S33
  • [33] A Randomized, Phase II Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating MetMAb and/or Bevacizumab in Combination with Weekly Paclitaxel in Patients with Metastatic Triple -Negative Breast Cancer.
    Daniel, B. R.
    Campone, M.
    Dieras, V.
    Ervin, T.
    Yu, W.
    Paton, V. E.
    Xia, Q.
    Peterson, A.
    CANCER RESEARCH, 2011, 71
  • [34] Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer
    Glueck, S.
    Lobo, C.
    Lopes, G.
    Castrellon, A.
    Hurley, J.
    Reis, I.
    Richman, S.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    EJC SUPPLEMENTS, 2010, 8 (03): : 196 - 196
  • [35] Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI)
    Yardley, Denise Aysel
    Bosserman, Linda D.
    Peacock, Nancy Walker
    Favret, Anne
    Morgan, Susan Kay
    Priego, Victor M.
    Bass, J. David
    Griner, Paula L.
    Burris, Howard A.
    Hainsworth, John D.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer
    Gradishar, W. J.
    Kaklamani, V
    Sahoo, Prasad T.
    Lokanatha, D.
    Raina, V
    Bondarde, S.
    Jain, M.
    CANCER RESEARCH, 2009, 69 (24) : 496S - 496S
  • [37] Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
    Krebs, Matthew G.
    Forster, Martin
    Majem, Margarita
    Peguero, Julio
    Iams, Wade
    Clay, Tim
    Roxburgh, Patricia
    Doger, Bernard
    Bajaj, Pawan
    Barba, Andres
    Perera, Suvini
    Mueller, Christian
    Triebel, Frederic
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
  • [38] Primary Results From Impassion131, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of First-Line Paclitaxel +/- Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 11 - 12
  • [39] Weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/NEU positive metastatic breast cancer (MBC):: final results of a multicenter randomized phase IIb trial
    Gasparini, G
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [40] Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A. M.
    Aldrighetti, D.
    Conte, P. F.
    Liu, D.
    Mudenda, B.
    McHenry, M. B.
    Pivot, X. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345